Phospho-MEF2A(Thr319)抗体特异性结合抗原：抗体本身不能直接溶解或杀伤带有特异抗原的靶细胞，通常需要补体或吞噬细胞等共同发挥效应以**病原微生物或导致病理损伤。然而，抗体可通过与病毒或**的特异性结合，直接发挥中和病毒的作用。
产品编号xy- 5485R
英文名称Phospho-MEF2A(Thr319)
中文名称磷酸化肌细胞增强因子2抗体
别 名MEF2A (phospho T319); p-MEF2A (phospho T319); MEF2A (Phospho-Thr319); MEF2A(phospho T319); myocyte enhancer-binding factor 2; ADCAD1; MADS box transcription enhancer factor 2 polypeptide A; MADS box transcription enhancer factor 2, polypeptide A (myocyte enhancer factor 2A); MEF 2A; MEF2; MEF2A; Myocyte enhancer factor 2A; RSRFC4; RSRFC9; Serum response factor like protein 1; MEF2A_HUMAN.
说 明 书100ul
产品类型磷酸化抗体
研究领域心血管 细胞生物 **学 染色质和核信号 神经生物学 信号转导 干细胞 转录调节因子
抗体来源Rabbit
克隆类型Polyclonal
Phospho-MEF2A(Thr319)抗体交叉反应 Human, Mouse, Rat, Dog, Cow, Horse, Sheep,
产品应用WB=1:500-2000 ELISA=1:500-1000 IHC-P=1:400-800 IHC-F=1:400-800 IF=1:100-500 （石蜡切片需做抗原修复）
not yet tested in other applications.
optimal dilutions/concentrations should be determined by the end user.
分 子 量54kDa
性 状Lyophilized or Liquid
浓 度1mg/1ml
免 疫 原KLH conjugated Synthesised phosphopeptide derived from human MEF2A around the phosphorylation site of Thr319:VT(P-T)PS
亚 型IgG
纯化方法affinity purified by Protein A
储 存 液0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol.
Phospho-MEF2A(Thr319)抗体保存条件Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year when kept at -20°C. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C.
PubMedPubMed
产品介绍background:
The process of differentiation from mesodermal precursor cells to myoblasts has led to the discovery of a variety of tissue-specific factors that regulate muscle gene expression. The myogenic basic helix-loop-helix proteins, including myoD (MIM 159970), myogenin (MIM 159980), MYF5 (MIM 159990), and MRF4 (MIM 159991) are one class of identified factors. A second family of DNA binding regulatory proteins is the myocyte-specific enhancer factor-2 (MEF2) family. Each of these proteins binds to the MEF2 target DNA sequence present in the regulatory regions of many, if not all, muscle-specific genes. The MEF2 genes are members of the MADS gene family (named for the yeast mating type-specific transcription factor MCM1, the plant homeotic genes 'agamous' and 'deficiens' and the human serum response factor SRF (MIM 600589)), a family that also includes several homeotic genes and other transcription factors, all of which share a conserved DNA-binding domain. MEF2A belongs to a family of DNA binding regulatory proteins. The MEF2 family of transcription factors is highly expressed in the brain when neurons undergo dendritic maturation and synapse formation. MEF2A is especially abundant in granule neurons of the cerebellar cortex throughout the period of synaptogenesis. MEF2A also has key roles in cardiac and skeletal muscle development.
Function:
Transcriptional activator which binds specifically to the MEF2 element, 5'-YTA[AT](4)TAR-3', found in numerous muscle-specific genes. Also involved in the activation of numerous growth factor- and stress-induced genes. Mediates cellular functions not only in skeletal and cardiac muscle development, but also in neuronal differentiation and survival. Plays diverse roles in the control of cell growth, survival and apoptosis via p38 MAPK signaling in muscle-specific and/or growth factor-related transcription. In cerebellar granule neurons, phosphorylated and sumoylated MEF2A represses transcription of NUR77 promoting synaptic differentiation.
Subunit:
Binds DNA as a homo- or heterodimer. Dimerizes with MEF2D. Interacts with HDAC7 (By similarity). Interacts with PIAS1; the interaction enhances sumoylation. Interacts with HDAC4, HDAC9 and SLC2A4RG. Interacts (via the N-terminal) with MAPK7; the interaction results in the phosphorylation and transcriptional activity of MEF2A.
Subcellular Location:
Nucleus.
Tissue Specificity:
Isoform MEF2 and isoform MEFA are expressed only in skeletal and cardiac muscle and in the brain. Isoform RSRFC4 and isoform RSRFC9 are expressed in all tissues examined.
Post-translational modifications:
Constitutive phosphorylation on Ser-408 promotes Lys-403 sumoylation thus preventing acetylation at this site. Dephosphorylation on Ser-408 by PPP3CA upon neuron depolarization promotes a switch from sumoylation to acetylation on residue Lys-403 leading to inhibition of dendrite claw differentiation. Phosphorylation on Thr-312 and Thr-319 are the main sites involved in p38 MAPK signaling and activate transcription. Phosphorylated on these sites by MAPK14/p38alpha and MAPK11/p38beta, but not by MAPK13/p38delta nor by MAPK12/p38gamma. Phosphorylation on Ser-408 by CDK5 induced by neurotoxicity inhibits MEF2A transcriptional activation leading to apoptosis of cortical neurons. Phosphorylation on Thr-312, Thr-319 and Ser-355 can be induced by EGF.
Sumoylation on Lys-403 is enhanced by PIAS1 and represses transcriptional activity. Phosphorylation on Ser-408 is required for sumoylation. Has no effect on nuclear location nor on DNA binding. Sumoylated with SUMO1 and, to a lesser extent with SUMO2 and SUMO3. PIASx facilitates sumoylation in postsynaptic dendrites in the cerebellar cortex and promotes their morphogenesis (By similarity).
Acetylation on Lys-403 activates transcriptional activity. Acetylated by p300 on several sites in diffentiating myocytes. Acetylation on Lys-4 increases DNA binding and transactivation (By similarity). Hyperacetylation by p300 leads to enhanced cardiac myocyte growth and heart failure.
Proteolytically cleaved in cerebellar granule neurons on several sites by caspase 3 and caspase 7 following neurotoxicity. Preferentially cleaves the CDK5-mediated hyperphosphorylated form which leads to neuron apoptosis and transcriptional inactivation.
DISEASE:
Defects in MEF2A are a cause of coronary artery disease, autosomal dominant, type 1 (ADCAD1)[MIM:608320]. A common heart disease characterized by reduced or absent blood flow in one or more of the arteries that encircle and supply the heart. Its most important complication is acute myocardial infarction.
Similarity:
Belongs to the MEF2 family.
Contains 1 MADS-box domain.
Contains 1 Mef2-type DNA-binding domain.
SWISS:
Q02078
Gene ID:
4205
Phospho-MEF2A(Thr319)抗体（antibody,
Ab）是由效应B细胞（效应**B细胞）分泌，机体用于抵御外来物质，如病毒，**等抗原，结构呈“Y”字型的球状蛋白质，仅仅存在于脊椎动物的血液和B**细胞膜表面。凡是能够跟抗体结合的物质，均被称作抗原，因此对于抗抗体（能够结合抗体的抗体）来说，抗体本身也是一种抗原物质。
Phospho-MEF2A(Thr319)抗体普通抗体重链和轻链的结构
重链结构：普通的**球蛋白具有2条重链（H链），分子量约为50kD,有μ、δ、γ、ε和α五种重链亚型，对应的**球蛋白名称分别为IgM、IgG、IgA、IgD和IgE。
轻链结构： 普通**球蛋白具有2条轻链（L链），分子质量约25kDa，有κ链和λ链两种亚型，这两种轻链决定了Ig的亚型类别（IgG1，IgG2，IgG3，IgG4）。一个天然的Ig分子两条轻链总是相同的，但在同一个体内可存在分别带有κ或λ链的抗体分子。不同种属生物体内两型轻链的比例不同，正常人血清**球蛋白κ链：λ链约为2：1，而在小鼠的比例为20：1。
2.2抗体Fab段和Fc段
IgG经木瓜蛋白酶酶切后裂解为2个完全相同的Fab段和1个Fc段,每个Fab段都为单价,可与抗原结合但不会再发生凝集反应；经胃蛋白酶酶切后裂解为1个完整F(ab)2片段和碎片化的Fc片段,F(ab’)2片段为双价,可同时结合两个抗原表位。Fab段为抗原结合片段（fragment of antigen binding，Fab），相当于抗体分子的两个臂，由一个完整的轻链和重链的VH和CH1结构域组成。Fc段为可结晶段（fragment crystallizable，Fc）相当于Ig的CH2和CH3结构域，是Ig与效应分子或者细胞相互作用的部位。Fab段包含完整的可变区，以及恒定区的CH1区域。Fc段仅指Ig恒定区CH2和CH3的区域，相当于Y字结构下面那一部分。
合格 合格 CD147 细胞外基质金属蛋白酶诱导因子抗体
合格 合格 SYK 非受体型酪氨酸蛋白激酶抗体
合格 PTEN 一种肿瘤抑制基因抗体（C端）
合格 OAS1 寡腺苷酸合成酶-1
合格 PEPT1 肠道肽转运蛋白1/小肽转运蛋白1抗体
合格 Ceramide glucosyltransferase 谷氨酸半胱氨酸γ合成酶抗体
合格 合格 LDL receptor 低密度脂蛋白受体抗体
合格 NF-H 高分子量神经丝蛋白抗体
合格 Collagen II Ⅱ型胶原α1蛋白/软骨钙素抗体
合格 合格 NF-M 中分子量神经丝蛋白抗体
合格 FAM3B 胰腺衍生因子抗体
合格 Beta Tubulin 微管蛋白抗体
合格 Smad2 细胞信号转导分子Smad-2抗体
合格 CEA 癌胚抗原抗体
合格 Estrogen Receptor alpha 雌**受体α抗体
合格 HSP27 热休克蛋白27/HSP25抗体
合格 合格 Cyclooxygenase 2 环氧合酶2/前列腺素内过氧化物合成酶2抗体
合格 ADAMTS7(NT) 整合素样金属蛋白酶与凝血酶1型-7抗体 (N端抗体)
合格 KGF 纤维母细胞生长因子7抗体
合格 FGF8 成纤维细胞生长因子8抗体
合格 CD56 神经细胞粘附分子1抗体
合格 HIF-1 Alpha 缺氧诱导因子1α 抗体HIF-1α
合格 Livin 凋亡抑制蛋白抗体
合格 CDKN2A/p16-INK4a 抑癌基因p16抗体
合格 CDKN1A/p21 p21蛋白抗体
合格 合格 CDKN1B/p27 KIP 1 P27抗体/周期素依赖激酶抑制剂
合格 合格 RANKL/CD254 骨保护蛋白配体/破骨细胞分化因子抗体
合格 合格 合格 PTEN 一种肿瘤抑制基因抗体（N端）